These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 7132765)
21. Biosynthesis and biological properties of prostaglandin endoperoxides and thromboxane A2. Svensson J Acta Biol Med Ger; 1978; 37(5-6):731-40. PubMed ID: 742285 [TBL] [Abstract][Full Text] [Related]
22. Preservation of ischemic myocardium by pinane thromboxane A2. Schrör K; Smith EF; Bickerton M; Smith JB; Nicolaou KC; Magolda R; Lefer AM Am J Physiol; 1980 Jan; 238(1):H87-92. PubMed ID: 7356037 [TBL] [Abstract][Full Text] [Related]
23. Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Burke SE; Lefer AM; Nicolaou KC; Smith GM; Smith JB Br J Pharmacol; 1983 Feb; 78(2):287-92. PubMed ID: 6831115 [TBL] [Abstract][Full Text] [Related]
24. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Le Breton GC; Venton DL; Enke SE; Halushka PV Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066 [TBL] [Abstract][Full Text] [Related]
25. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Samuelsson B Biosci Rep; 1983 Sep; 3(9):791-813. PubMed ID: 6315101 [No Abstract] [Full Text] [Related]
26. Synthesis and in vitro pharmacology of 7-oxabicyclo[2.2.1]heptane analogues of thromboxane A2/PGH2. Sprague PW; Heikes JE; Gougoutas JZ; Malley MF; Harris DN; Greenberg R J Med Chem; 1985 Nov; 28(11):1580-90. PubMed ID: 4067988 [TBL] [Abstract][Full Text] [Related]
27. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Smith JB; Araki H; Lefer AM Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350 [TBL] [Abstract][Full Text] [Related]
28. Prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation of rabbit platelets. Lewis GP; Watts IS Br J Pharmacol; 1982 Apr; 75(4):623-31. PubMed ID: 6802211 [TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamino pinane derivatives). Katsura M; Miyamoto T; Hamanaka N; Kondo K; Terada T; Ohgaki Y; Kawasaki A; Tsuboshima M Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():351-7. PubMed ID: 6221545 [No Abstract] [Full Text] [Related]
30. Carbocyclic thromboxane A2: aggrevation of myocardial ischemia by a new synthetic thromboxane A2 analog. Smith EF; Lefer AM; Aharony D; Smith JB; Magolda RL; Claremon D; Nicolaou KC Prostaglandins; 1981 Mar; 21(3):443-56. PubMed ID: 7232768 [TBL] [Abstract][Full Text] [Related]
31. Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Halushka PV; Kochel PJ; Mais DE Br J Pharmacol; 1987 May; 91(1):223-7. PubMed ID: 3594077 [TBL] [Abstract][Full Text] [Related]
32. Thromboxane A2 analogues inhibit the metabolism of thromboxane B2 in perfused guinea-pig lung. Robinson C; Hoult JR Biochim Biophys Acta; 1983 Nov; 754(2):190-200. PubMed ID: 6652102 [TBL] [Abstract][Full Text] [Related]
33. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium. Pollock WK; Armstrong RA; Brydon LJ; Jones RL; MacIntyre DE Biochem J; 1984 May; 219(3):833-42. PubMed ID: 6234886 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of coronary vasoconstriction induced by carbocyclic thromboxane A2. Smith EF; Lefer AM; Nicolaou KC Am J Physiol; 1981 Apr; 240(4):H493-7. PubMed ID: 6261592 [TBL] [Abstract][Full Text] [Related]
35. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis]. Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305 [No Abstract] [Full Text] [Related]
36. Synthesis and platelet antiaggregatory activity of trimetoquinol analogs as endoperoxide/thromboxane A2 antagonists. Harrold MW; Gerhardt MA; Romstedt K; Feller DR; Miller DD Drug Des Deliv; 1987 Feb; 1(3):193-207. PubMed ID: 3509333 [TBL] [Abstract][Full Text] [Related]
37. Fatty acids bound to serumalbumin decrease the half-life of thromboxane A2. Lagarde M; Velardo B; Blanc M; Dechavanne M Prostaglandins; 1980 Aug; 20(2):275-83. PubMed ID: 7413992 [TBL] [Abstract][Full Text] [Related]
38. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor. Johnson GJ; Dunlop PC; Leis LA; From AH Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295 [TBL] [Abstract][Full Text] [Related]
39. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists. Hanasaki K; Arita H Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of human platelet thromboxane synthetase by 11a-carbathromboxane A2 analogs. Gorman RR; Maxey KM; Bundy GL Biochem Biophys Res Commun; 1981 May; 100(1):184-90. PubMed ID: 7196228 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]